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Acute Lung Injury/Acute Respiratory Distress
Syndrome
F. H. Khan ( Department of Anesthesia, The Aga Khan University Hospital, Karachi. )

Reports of pulmonary physiopathological insults following severe trauma resulting in respiratory
failure are not new in medical literature1,2. In 1967 Ashbaugh and colleagues described a syndrome of
acute respiratory distress following a variety of precipitating conditions 3. Severe hypoxemia, diffuse
pulmonary infiltrates, poor lung compliance and absence of left heart failure characterize this
condition. Ashbaugh et al4 subsequently named it as adult respiratory distress syndrome to differentiate
it from infant respiratory distress syndrome. It was proposed at that time that both conditions manifest
similar physiopathological changes. It was also referred to as “traumatic wet lung”, “congestive
atelectasis”, or “Da Nang lung” and had a high mortality rate.
Since these initial reports, researchers focused their attention towards ARDS in order to find out the
precipitating factors and therapeutic measures one can take to treat it. From these observations emerged
this concept that different systemic conditions and variety of insults to the lung are associated with
ARDS clinical syndrome5 and that it should be regarded as an extreme manifestation of a process
called Acute Lung Injury (ALL). Murray quantified the severity of ARDS for determination of
prognosis of patients suffering from this clinical syndrome. In 1988, he proposed an AL! score6 based
on four components i.e., the extent of infiltration on patients chest x-ray, degree of hypoxemia, amount
of positive end expiratory pressure (PEEP) used to oxygenate the patient and the patients respiratory
system compliance when available.
Definitions and Diagnostic Criteria
In order to resolve the controversy about definitions, precipitating conditions and diagnostic criteria for
ARDS, an American European Consensus conference (AECC) wase held in 1994. This consensus
conference7 report declared "the daifficaulty in determining the incidence and outcome of ARDS is
largely due to the heterogeneity and lack of definitions for the underlying disease process [and] the lack
of definition for ARDS". Despite controversy, the consensus conference ultimately recommended that
"acute lung injury" (ALI) be defined as a syndrome of inflammation and increasing permeability. It is
associated with a constellation of clinical, radiological and physiologic abnormalities that cannot be
explained by, but may coexist with left atrial or pulmonary capillary hypertension and that ARDS be
defined simply as a more severe form of ALL. The consensus conference also urged that there should
be a return to the original term “acute” rather than “adult” in recognition that ARDS is not limited to
adults only.
AECC members proposed the following diagnostic criteria for AL! and ARDS:
a) Acute onset
b) Bilateral chest radiographic infiltrates
c) Pulmonary artery occlusion pressure of <18 mmHg or no evidence of left atrial hypertension and
d) Impaired oxygenation regardless of PEEP administration with a Pa02 / Fi02 ratio of<300 mmHg
for AL! and <200 mmHg for ARDS.
Although debate exists as to the utility of these criteria and the radiographic criteria of bilateral (but not
diffuse) chest infiltrates for AL! and ARDS is nonspecific, these criteria are most widely accepted by
clinical investigators.
Shuster8 in 1995 emphasized on the importance of linking structural changes with functional
abnormalities; that results in ARDS. He defined AL! to be present when characteristic pathological

abnormalities in the lung result in deterioration of normal lung function, and ARDS to be a specific
form of lung injury with diverse causes, characterized pathologically by diffuse alveolar damage and a
breakdown in both the barrier and gas exchange functions of the lung, resulting in proteinaceous
alveolar edema and hypoxem ia.
Incidence of AL! and ARDS
The incidences of AL! and ARDS are not clear. A national institute of health panel in 1972 estimated
the incidence of ARDS to be 150,000 cases per year in the United States9. Recent prospective studies
have shown a much lower incidence of ARDS ranging from 1.5 to 8.4 cases per 100.000 populations
per year10,11. All of these studies were performed before the AECC definitions were developed. Data
on the incidence of either AL! or ARDS using AECC criteria have not yet been published.
in ongoing studies of ALI and ARDS at harbor view medical center, university of Washington based on
AECC friteria the incidence of ARDS 12.6/1000,000/year and the incidence of ALI and ARDS by
AECC criteria is likely to be considerably higher than the recent prospective studies would indicate.
However this remains to be confirmed.
Risk Factors for ALl and ARDS
Risk factors or etiologic factors for either conditions are associated with ARDS or markers that occur in
conditions known to be associated with ARDS. These associated conditions are direct (primary) i.e.
resulting in direct injury to the lung such as aspiration, lung infection, lung contusion or other
inhalational injuries. Indirect (secondary) predisposing factors are sepsis, multiple trauma, bums,
shock, acute pancreatitis and massive transfusion injuries to the lung through activation of systemic
inflammation, presumably related in part to elevated cytokine levels and other biochemical and
chemical mediators.
Pathogenesis
Regardless of whether the primary etiology originates within or outside the lung, a systemic
inflammatory response accompanies and may determine the progression of AL!. Chemotaxis and
activation of leukocytes lead to the release of cytotoxic free radicals and cytokines such as tumor
necrosis factor and the interleukins. The expression of leukocytes adhesion molecules and proteases
contribute to epithelial and endothelial injury12. A number of homeostatic systems are activated: the
compliment and kinin system, the coagulation cascade, the cyclo-oxygenase and leukotrienes pathway
and the NO- elevated cytokine levels and other biochemical and chemical mediators.
Pathogenesis
Regardless of whether the primary etiology originates within or outside the lung, a systemic
inflammatory response accompanies and may determine the progression of AL!. Chemotaxis and
activation of leukocytes lead to the release of cytotoxic free radicals and cytokines such as tumor
necrosis factor and the interleukins. The expression of leukocytes adhesion molecules and proteases
contribute to epithelial and endothelial injury12. A number of homeostatic systems are activated: the
compliment and kinin system, the coagulation cascade, the cyclo-oxygenase and leukotrienes pathway
and the NO-cyclic guanosine monophosphate pathway. The systemic inflammatory process
contributing to acute lung injury is complex. These complex processes interact to cause increase in
shunt fraction, decrease in pulmonary compliance, increase in airway resistance, ventilation perfusion
imbalance and pulmonary hypertension.
Phases of ALl / ARDS
Initial Phase
During the first 3-5 days of respiratory failure, there is an increase in the permeability of the endothelial
and epithelial barriers of the lung with accumulation of protein rich edema fluid in the interstitial and
air spaces of the lung13. This results in severe defect in oxygenation, a reduction in lung compliance
and bilateral pulmonary infiltrates14. Some of the studies have shown that during this phase there is
either production of abnormal surfactant or inactivation of surfactant by the protein rich edema

fluid15,16. The edema fluid contains a variable quantity of red blood cells, white blood cells, hyaline
membranes, (which consists of albumin, immunoglobulin, fibrin, fibrinogen and other proteins)17. This
has been given the name of diffuse alveolar damage. Some patients recover from this insult where as
others pass into a sub-acute or chronic phase of lung injury18.
Sub-acute Phase
This phase, which develops 5-7 days after the onset of lung injury, is characterized physiologically by
an increase in alveolar dead space, necessitating a high minute ventilation to achieve a normal or near
normal PaCO2. There is also a persistent oxygenation defect as well as decrease in the lung
compliance.
There is evidence of interstitial fibrosis with proliferation of alveolar type 2 cells and both obstruction
and destruction of portions of microcirculation of lungs19-21. During this phase there are usually
persistently large unchanging bilateral infiltrates on chest X-ray.
Chronic Phase
When the patient survives these phases there is a gradual transition to a chronic phase of lung injury
with persistently low lung compliance and a markedly elevated dead space fraction. There is
pathological evidence of extensive pulmonary fibrosis with obliteration of normal alveolar architecture
and progressive development of emphysematous region of the lungs including the development of
discrete emphysematous bullae, which can be observed by CT Scan only22.
Management
The management of ARDS is complex. It consists of supportive management that supports the
physiologic abnormalities and returns them towards normal but which has no fundamental effect on the
underlying mechanism of lung injury, and that, which is definitive, i.e. which affects the mechanism of
injury. A large number of management strategies have been proposed in the literature mostly involving
animal models. Some of the management strategies that have been evaluated in humans over the last
10-15 years shall be reviewed here.
Ventilatory Management
Many new forms of mechanical ventilatory support for patients with ARDS have been proposed.
The goals of ventilatory management23 in patients with ARDS are to:
Ensure appropriate oxygen delivery to vital organs along with sufficient CO2 removal
Minimize oxygen toxicity
Recruit alveoli
Minimize high airway pressure
Prevent atelectasis
Use sedation and paralysis judiciously
In order to achieve the above-mentioned goals of ventilatory management, a number of ventilatory
strategies have been proposed and these are:
Permissive Hypercapnia
Low tidal volume strategy has shown beneficial effects in patients with ALI/ARDS24. Here the tidal
volume is reduced to between 5-7 ml/kg of the body weight. The PaCO2 is slowly allowed to rise
giving the time to the body to compensate for this respiratory acidosis. It is suggested that pH as low as
7.15 or 7.2 may be well tolerated in the absence of significant cardiac or central nervous system
abnormalities25. One recent study in animal model has shown that therapeutic Hypercapnia protects
against ALl26.
Pressure Controlled Ventilation
In order to minimize the high airway pressure in patients with ALI/ARDS, pressure controlled
ventilation is currently the most favoured mode used by intensivist all over the world. In the pressure
control mode, the pre set time factors trigger gas flows that continues until a predetermined pressure is

achieved in the proximal airway. The pressure controlled mode provides very rapid initial flows that
later on decelerate. The theoretical advantage of this rapid initial flow includes better gas mixing and
improved patient synchrony. Assuming an adequate inspiratory time, the delivered tidal volume will be
determined by the pre set airway pressure and the pulmonary compliance. Therefore if there is a
significant decrease in the compliarìce of patients lung than the tidal volume delivery can decrease.
Inverse Ratio Ventilation
Inverse ratio ventilation is an alternative method of limiting excessive airway pressures. In inverse ratio
ventilation the inspiratory time is prolonged thereby increasing mean airway pressure while
maintaining peak airway pressures27. Selecting an inspiratory / expiratory ratio greater than 1:1 may
allow for recruitment of non compliant, surfactant deficient alveoli and more homogeneous gas
delivery. The maximal benefit of inverse ventilation on gas exchange may take several hours to
achieve, which supports the hypothesis that sustained inspiratory pressure is one mechanism of benefit
with its use. Based on clinical experience it has been shown to improve gas exchange in patients with
ARDS who failed to maintain oxygenation with conventional ventilation using PEEP28.
However a recent randomized, cross over study failed to show any improvement with inverse ratio
ventilation29. As it has not been well studied and is uncomfortable for the patient requiring high dose of
sedation or neuromuscular blockade, it is currently not recommended as the initial ventilatory approach
in all patients with ALI/ARDS. I’Iowever it can be considered in patients with refractory hypoxaemia
requiring high Fi02, or when the use of PEEP is associated with excessive peak air way pressures.
Positive end expiratory pressure (PEEP)
PEEP has a definite role in recruiting and stabilizing injured alveoli30. This improves ventilation
perfusion mismatch and lung compliance. Acute lung injury is a heterogeneous condition so PEEP
applied to the patient may be appropriate in one region of the lung but may cause over distention in the
other. It may be sub-optimal in the third region. It is therefore of paramount importance to select best
PEEP in the patients with ARDS to avoid the deleterious effects. PEEP in the range of 5-15 cms H20
has been found to provide a reasonable balance between these effects31. One can increase the PEEP
above 15 cms H20, but this usually will result in over distention of already recruited alveoli. For this
reason PEEP level >20 cms of H20 or PEEP levels associated with plateau pressure of>35 cms of H20
are generally avoided32.
Fluid Management
There has always been a controversy regarding optimal fluid management in patients with ARDS. This
controversy revolves around which fluid to use and whether to use fluid or not. There are few who
advocate keeping the patient with ARDS relatively dry either by diuretics or restricting fluids whereas
others favor fluid administration to maintain DO2, cardiovascular and renal function33.
Those who favour fluid restriction base their arguments on theoretical, experimental and clinical data.
Experimental studies have indicated that pulmonary functions and outcome are better in patients who
achieve a negative fluid balance where as positive fluid balance results in worse outcome34-36.
Recommendations are to maintain a lower pulmonary artery wedge pressure by either restricting fluid
or by using diuretics especially during the first few days of onset of ARDS37. However at a later stage
fluid restriction is of no benefit specially when fibrosis has occurred. One should be careful about
aggravating renal function and to avoid problems from fluid restriction a pulmonary artery wedge
pressure monitoring is essential38.
Prone positioning
The infiltrates in the lungs of patients with ALL / ARDS are not evenly distributed therefore by
changing the position of patient one can get improvement in gaseous exchange39. If there is more
involvement of one lung, then the lateral decubitus position may benefit the patient. The patient should
be in a position in which the less diseased lung is dependent in order to match ventilation and

perfusion. Prone position to improve oxygenation in patients with ARDS has been proposed in many
studies40. The prone position is beneficial because it generates a transpulmonary pressure sufficient to
exceed airway-opening pressure in dorsal lung regions where atelectasis, shunt and ventilation
perfusion mismatch occurs41. This approach should be used only in centers experienced with it because
of the problems and complications associated with prone position42. A randomized controlled trial
which was done in 35 Italian intensive care units showed an improvement in oxygenation of 85% after
6 hours of prone positioning39.
Nitric Oxide
Nitric oxide is a potent pulmonary vasodilator. When given by inhalation in small doses, it causes
vasodilatation of ventilated areas. Blood is directed from the poorly or non-ventilated areas to better
ventilated areas of lung and improvement in ventilation perfusion mismatch and reduction in
intrapulmonary shunting occurs. The nitric oxide is blended with oxygen and administered to the
patient in parts per million. The optional dose of nitric oxide inhalational therapy is not determined but
response may be patient specific or related to the severity of ARDS. Side effects of high concentration
of nitric oxide are methemoglobinaem ia, acute pulmonary edema and acidemia but the likelihood of
toxicity from prolonged inhalation of Nitric oxide (2-20 ppm) is minimal43. There are published data
that indicates that nitric oxide reduces pulmonary artery pressure and shunt. It also increases Pa02/Fi02
ratio without affecting cardiac output or systemic arterial pressure. However a recent randomized trial
of 177 patients using 4 doses of nitric oxide failed to show any improvement in oxygenation or
duration of mechanical ventilation44. Other clinical trials in adults have failed to show any benefit on
mortality or on mechanical ventilation requirements45. Nitric oxide can be considered a rescue therapy
in patient with ARDS refractory to conventional modes of ventilation and gas exchange support.
Corticosteroids
The ability of corticosteroids to attenuate host inflammatory response has provided the rationale for
their use in ARDS. Large prospective studies in the mid 80s failed to demonstrate increased survival
when high dose steroids were used in early phases of ARDS46.
In refractory or late ARDS corticosteroids improve important physiological values. Criteria that
investigators used for prescribing steroids for late ARDS were:
• No improvement for at least 72 hrs with maximum ventilatory support
• When no other therapeutic options were available
• Progressive respiratory failure with worsening lung injury score
• No evidence of active infection.
There has been only one prospective randomized trial47a pilot study of 24 patients, which suggests that
this therapy may be beneficial corticosteroids may have an important role in patients with late ARDS48.
Large prospective trials are needed to determine specific target patient characteristic, timing of the start
of therapy and optimal dosage and duration of therapy.
Surfactant Replacement Therapy
In ALl surfactant becomes dysfunctional because of altered composition and disruption of the
continuity of the surfactant layer by pulmonary edema fluid and neutrophilic infiltration49. Surfactant
replacement therapy has been evaluated in the infant respiratory distress syndrome with recognized
benefits50.
Exogenous surfactant administration in adult human has been investigated in many studies that have
shown trends towards increased survival but no difference in other measured parameters were noted51.
A prospective, multicentre, double blind, randomized, placebo controlled study involving more than
700 patients with sepsis induced ARDS has failed to show any benefit of exogenous surfactant
administration by continuous aerosol52. However one of the recently published study concluded that
the pulmonary response to exogenous surfactant after mechanical ventilation is experimental. AL! is

improved when a ventilatory strategy with high PEEP is used53.
Surfactant still may show promise in specific subgroups of ARDS, or may have a role in the treatment
of patients with high risk of syndrome. Dosage, mode of delivery, timing of therapy and its use in
combination with other agents are areas where it deserves prospective trials before final decisions can
be made to eliminate it from the treatment options for ARDS.
Outcome
Factors associated with mortality include risk factors and age. Patients developing ARDS secondary to
sepsis have a considerably higher mortality then most other common risk factors54. Older patients
greater than 65 years of age have an increased mortality rate55.
The severity of ARDS at the time of first diagnosis as measured by oxygenation abnormality (Pa02 I
FiO2) has generally not been associated with differing outcomes. Kraffl et al56 in a meta analysis of
102 publications on ARDS found no correlation between PaO2/Fi02 and mortality. The most common
cause of death in patients with ARDS is sepsis and multiple organ failure rather than hypoxia57,58.
Conclusion
ALI/ARDS is a complex response of the lung to direct and indirect insults. Treatment of ALI/ ARDS is
mainly supportive at the moment. Ventilatory management is the mainstay of supportive therapy and
many new ventilatory strategies have been proposed. Attention has been turned to prevention of
iatrogenic lung damage by use of pressure controlled ventilation and permissive hypercapnia, thus
limiting the rise in peak airway pressure. For those with refractory hypoxaemia, inverse ratio
ventilation, use of nitric oxide and prone position do offer some improvement in oxygenation.
Most of the deaths in patients with ALI/ARDS is secondary to multiple organ failure. There is therefore
a need to evolve strategies to prevent the development of non-pulmonary organ dysfunction in these
patients.
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